Advertisement
U.S. markets close in 26 minutes

Hoth Therapeutics, Inc. (HOTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3197+0.0497 (+3.91%)
As of 02:59PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.2700
Open1.2700
Bid1.2800 x 1400
Ask1.3600 x 800
Day's Range1.2643 - 1.3300
52 Week Range0.9900 - 4.3000
Volume87,589
Avg. Volume262,485
Market Cap5.736M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-4.7100
Earnings DateMar 31, 2024 - Apr 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HOTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Hoth Therapeutics, Inc.
    The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But the tide turned in 2022. The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • PR Newswire

    Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

    Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it will continue its work with Venable, LLP to develop and protect its intellectual property. Venable is an American Lawyer Global 100 law firm that serves as primary counsel to a worldwide clientele of large and mid-sized organizations and nonprofits and individuals. With more than 900 professionals across the country, the firm strategically advances its clients' objectives in the United Sta

  • PR Newswire

    Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The

  • PR Newswire

    Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO CEO and Investor Conference in New York, NY.